Related Experiment Video
Updated: May 28, 2026
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Novel agents in Waldenström macroglobulinemia
Ghayas C Issa1, Irene M Ghobrial, Aldo M Roccaro
1Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA.
Clinical Investigation
|October 29, 2011
Summary
Novel targeted therapies show significant efficacy in treating Waldenström macroglobulinemia (WM), a rare B-cell cancer. These new agents offer improved response rates and potential for longer remissions compared to traditional treatments.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Waldenström macroglobulinemia (WM) is an incurable B-cell malignancy.
- Current treatments include alkylating agents, nucleoside analogues, and anti-CD20 antibodies.
- Understanding WM pathogenesis and microenvironment interactions is crucial for developing new therapies.
Purpose of the Study:
- To review novel therapeutic agents for Waldenström macroglobulinemia.
- To highlight agents that have entered clinical trials for WM treatment.
- To discuss the potential impact of these novel agents on patient outcomes.
Main Methods:
- Review of preclinical and clinical trial data for novel WM therapies.
- Focus on agents targeting specific signaling pathways and cellular interactions.
- Analysis of response rates and potential for improved patient quality of life.
Main Results:
- Novel agents demonstrate overall response rates ranging from 25% to 96%.
- Ongoing trials investigate agents like enzastaurin, carfilzomib, LBH589, ofatumumab, and bendamustine.
- These therapies offer potential for higher responses and longer remissions.
Conclusions:
- Novel therapeutic agents are significantly improving treatment efficacy for WM.
- Future WM treatment paradigms will likely incorporate these targeted therapies.
- These advancements promise better quality of life for WM patients.
